Kumara H M C Shantha, Sutton Elie, Caballero Otavia L, Su Tao, Yan Xiaohong, Ahmed Aqeel, Herath Sonali A C, Cekic Vesna, Njoh Linda, Kirchoff Daniel D, Whelan Richard L
Division of Colon and Rectal Surgery, Department of Surgery, Lenox Hill Hospital, Northwell Health, New York, NY 10028, USA.
Department of Surgery, Mount Sinai West Hospital, New York, NY 10019, USA.
Oncotarget. 2021 Mar 2;12(5):412-421. doi: 10.18632/oncotarget.27897.
Calcium-binding tyrosine phosphorylation-regulated protein (CABYR) is expressed in the human germ line but not in adult human tissues, thus, it is considered a cancer testis protein. The aim of this study is to evaluate the CABYR isoforms: a/b and c mRNA expression in colorectal cancer (CRC) and to determine if these proteins hold promise as vaccine targets.
CABYR mRNA expression in a set of normal human tissues, including the testis, were determined and compared using semi-quantitative PCR. As regards the tumor and normal mucosal samples from study patients, RNA was extracted and cDNA generated after which quantitative PCR was carried out. Analysis of CABYR protein expressions by immunohistochemistry in tumor and normal colon tissues was also performed.
A total of 47 paired CRC and normal tissue specimens were studied. The percent of patients with a relative expression ratio of malignant to normal (M/N) tissues over 1 was 70% for CABYR a/b and 72% for CABYR c. The percent with both a M/N ratio over 1 and expression levels over 0.1% of testis was 23.4% for CABYR-a/b and 25.5% for CABYR c. CABYR expression in tumors was further confirmed by immunohistochemistry.
CABYR a/b and c hold promise as specific immunotherapy targets, however, a larger and more diverse group of tumors (Stage 1-4) needs to be assessed and evaluation of blood for anti-CABYR antibodies is needed to pursue this concept.
钙结合酪氨酸磷酸化调节蛋白（CABYR）在人类生殖系中表达，但在成人组织中不表达，因此，它被认为是一种癌胚蛋白。本研究的目的是评估CABYR亚型：a/b和c在结直肠癌（CRC）中的mRNA表达，并确定这些蛋白是否有望成为疫苗靶点。
使用半定量PCR测定并比较一组正常人类组织（包括睾丸）中CABYR mRNA的表达。对于研究患者的肿瘤和正常黏膜样本，提取RNA并生成cDNA，然后进行定量PCR。还通过免疫组织化学分析了肿瘤和正常结肠组织中CABYR蛋白的表达。
共研究了47对CRC和正常组织标本。CABYR a/b恶性与正常（M/N）组织相对表达率超过1的患者百分比为70%，CABYR c为72%。CABYR-a/b M/N比超过1且表达水平超过睾丸0.1%的患者百分比为23.4%，CABYR c为25.5%。免疫组织化学进一步证实了肿瘤中CABYR的表达。
CABYR a/b和c有望成为特异性免疫治疗靶点，然而，需要评估更大且更多样化的肿瘤组（1-4期），并检测血液中的抗CABYR抗体以推进这一概念。
